Clinical and Cost Effectiveness of Apixaban Compared to Aspirin in Patients with Atrial Fibrillation: An Australian Perspective

ConclusionCompared to aspirin, apixaban is likely to be cost effective in preventing thromboembolic disease among VKA unsuitable patients with atrial fibrillation.

http://link.springer.com/10.1007/s40258-016-0283-9

Source: Applied Health Economics and Health Policy - October 3, 2016 Category: Health Management Source Type: research